Navigation Links
Alvespimycin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...osium). Kosan has expanded this Phase 1 trial to include the combination of alvespimycin plus trastuzumab and paclitaxel (Taxol(R)). In the first quarter 2008, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy in patients with HER2-positive metastatic breast cancer who ...

Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
Alvespimycin in Medical Technology

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...sion on Monday, June 2, 2008 at 8:00 am to 11 am CT. Abstract 2502, titled, "First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: alvespimycin (A) administered QOD or QD," will be presented at 8:00 to 8:15 am CT in room W375a by Keith Flaherty, M.D., of the University of Pennsylvania. About...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...ients with HER2-positive metastatic breast cancer. alvespimycin has demonstrated the potential to disrupt the acti... to evaluate the safety and anticancer activity of alvespimycin as a single agent in patients who have not previou...ium demonstrated encouraging antitumor activity of alvespimycin in combination with trastuzumab (Herceptin(R)). ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...ting in June Phase I Trial Expanding to Include alvespimycin Plus Trastuzumab Plus Pa.... We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establ...his year. We believe that the clinical activity of alvespimycin seen in our breast cancer Phase 1 trials to date v...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

...combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

... initiation of our TIME registration program for tanespimycin in patients with multiple myeloma, and with plans underway to advance second- generation alvespimycin into later-stage trials in patients with HER2-positive metastatic breast cancer, we look forward to further characterizing the efficacy and safety pro...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...apolis, IN, in a poster, titled, "Phase 1 Trial of alvespimycin (KOS-1022; 17-DMAG) and Trastuzumab," at the 2007 ...leadership in the Hsp90 inhibitor area." Phase 1 alvespimycin Results alvespimycin is a second-generation Hsp90 inhibitor that has de...
Alvespimycin in Biological Technology

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

... demonstrated potential activity. -- Kosan will withdraw Hsp90 inhibitor alvespimycin from development in order to commit resources to the development of ta...tabine(R)) and/or Herceptin(R). Kosan plans to discontinue development of alvespimycin in lieu of development of tanespimycin. The process of ending current alves...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...

Kosan Announces Third Quarter 2007 Financial Results

...e presentation of updated positive Phase 1 data on alvespimycin in HER2-positive metastatic breast cancer; Phase 1...a Phase 2 monotherapy trial of our Hsp90 inhibitor alvespimycin in newly-diagnosed patients with HER2-positive met...cal trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated antitumor activity and tolerabili...

Kosan to Reacquire Epothilone Program From Roche

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Biosciences to Host Research & Development Day on October 31, 2007

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhib...

Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
Other Tags
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... 17, 2014 Giving patients adrenaline after they suffer a ... their prospects of surviving long-term, according to new research ... of patients who have a cardiac arrest get adrenaline, ... arrest for decades," said Dr. Steve Lin, an emergency ... despite advances in medical treatment, long-term survival rates of ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
(Date:4/17/2014)... in the Amazon help create tinderbox conditions for ... widespread forest loss during drought years, according to ... forests in the Amazon could reach a "tipping ... lead to large-scale loss of trees, making recovery ... geography, Penn State. , "We documented one of ...
(Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
(Date:4/17/2014)... genetic information of DNA is used to manufacture ... different functions in living organisms. Messenger RNA (mRNA) ... by relating the genetic information of DNA to ... , By examining the different types and amounts ... a given time, researchers can determine which specific ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2
Other Contents